Moleculin Biotech Announces New Annamycin Data Presentations in Sept 2026

What Happened
Moleculin Biotech, Inc. (MBRX) filed a Form 8‑K on September 14, 2026, disclosing a press release that new data on its lead drug candidate Annamycin (naxtarubicin) will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development. The presentations cover three distinct questions: where Annamycin concentrates in the body, how it kills cancer cells, and whether it can recruit the immune system to attack tumors. A copy of the press release is attached as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: September 14, 2026 (Form 8‑K, Item 7.01, Regulation FD Disclosure).
• Drug: Annamycin (naxtarubicin), the company’s lead candidate.
• Events: Data to be presented at three scientific venues in September 2026, including AACR’s Conference on Pancreatic Cancer.
• Exhibit: Press release announcing the presentations attached as Exhibit 99.1.

Why It Matters
These scientific presentations provide investors with new, non‑financial information about Annamycin’s pharmacology, mechanism of action, and potential immune effects—data that can shape expectations for the drug’s development in hard‑to‑treat cancers. While the filing does not include clinical results or financial updates, the disclosure signals ongoing research activity and potential milestones to watch in the company’s oncology pipeline.